Page 133 - Haematologica Vol. 107 - September 2022

ARTICLE - Effects of BT200 on VWF/FVIII in humans
K.D. Kovacevic et al.
novel N-linked glycosylation. J Thromb Haemost.
2020;18(6):1278-1290.
24. Yamamoto K, Troeberg L, Scilabra SD, et al. LRP-1-mediated
endocytosis regulates extracellular activity of ADAMTS-5 in
articular cartilage. FASEB J. 2013;27(2):511-521.
25. Gerritsen KG, Bovenschen N, Nguyen TQ, et al. Rapid hepatic
clearance of full length CCN-2/CTGF: a putative role for LRP1- mediated endocytosis. J Cell Commun Signal. 2016;10(4):295-303.
26. Kearon C, de Wit K, Parpia S, et al. Diagnosis of pulmonary embolism with d-dimer adjusted to clinical probability. N Engl J Med. 2019;381(22):2125-2134.
27. Kovacevic KD, Greisenegger S, Langer A, et al. The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients. Sci Rep. 2021;11(1):3092-3101.
28. Kovacevic KD, Buchtele N, Schoergenhofer C, et al. The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin. Sci Rep. 2020;10(1):11180.
29. O'Sullivan JM, Ward S, Lavin M, O'Donnell JS. von Willebrand factor clearance - biological mechanisms and clinical significance. Br J Haematol 2018;183(2):185-195.
30. Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood. 2016;128(16):2007-2016.
31. Chion A, Aguila S, Fazavana J, et al. VWFA1 interacts with scavenger receptor LRP1 via lysine 1408. Res Pract Thromb Haemost. 2019;3(S1):1-228.
32. Martin K, Key NS. How I treat patients with inherited bleeding
disorders who need anticoagulant therapy. Blood.
2016;128(2):178-184.
33. Zhu S, Gilbert JC, Liang Z, et al. Potent and rapid reversal of the
von Willebrand factor inhibitor aptamer BT200. J Thromb
Haemost. 2020;18(7):1695-1704.
34. Deitcher SR, Tuller J, Johnson JA. Intranasal DDAVP induced
increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. Haemophilia. 1999;5(2):88-95.
35. Lethagen S. Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety. Semin Thromb Hemost. 2003;29(1):101-106.
36. Casonato A, Daidone V, Galletta E, Bertomoro A. Type 2B von Willebrand disease with or without large multimers: a distinction of the two sides of the disorder is long overdue. PLoS One. 2017;12(6):e0179566.
37. Casonato A, Gallinaro L, Cattini MG, et al. Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia. Haematologica. 2010;95(8):1366-1372.
38. Casari C, Lenting PJ, Wohner N, Christophe OD, Denis CV. Clearance of von Willebrand factor. J Thromb Haemost. 2013;11(Suppl 1):202-211.
39. Casonato A, Pontara E, Sartorello F, et al. Identifying type Vicenza von Willebrand disease. J Lab Clin Med. 2006;147(2):96-102.
40. van Galen KPM, d'Oiron R, James P, et al. A new hemophilia carrier nomenclature to define hemophilia in women and girls: communication from the SSC of the ISTH. J Thromb Haemost. 2021;19(8):1883-1887.
Haematologica | 107 September 2022
2132